Printer Friendly

Using Lab-Grown Olfactory Stem Cells To Research Nasal Injury Recovery.

BOSTON, Mass., March 28, 2019 -- A team of researchers here has developed a method to grow and maintain olfactory stem cells in culture, which can then be used to restore tissue in the nose.

The discovery by scientists at Tufts University School of Medicine raises hope that future therapies could be developed to restore the sense of smell in individuals where it has been damaged by injury or degeneration.

The stem cells, called horizontal basal cells (HBCs), can repopulate all olfactory epithelium (OE) cell types, including sensory neurons, when transplanted into injured tissue.

The development may pave the way for further research into stem cell transplantation therapies, or pharmacological approaches that stimulate stem cells within the nose to regenerate tissue.

The nerves that confer the sense of smell are unique when compared to the rest of the nervous system, in that they can trigger a robust and nearly complete regenerative response after injury.

OE tissue contains two types of stem cells--globose basal cells (GBCs) and HBCs. The GBCs have been successfully cultured and appear to have a primary role in repopulating cells that have been lost to routine turnover.

HBCs, however, remain dormant and are not activated until there is an injury.

Unfortunately, studies on these cells have been limited by the fact that they could not be expanded and maintained in culture.

In this study, the researchers determined the optimal conditions for expanding and maintaining healthy HBC stem cells in culture, borrowing methods and factors used to maintain respiratory stem cells.

"Once we determined that we could grow HBCs in the lab, and that they expressed the same identifying molecular markers found in vivo, we sought to confirm whether they would work as well as the in vivo HBCs--can they regenerate tissue that has been injured --and they did!" said James Schwob, corresponding author.

Despite a natural ability for regeneration, dysfunction in the sense of smell is still reported among 19.4 percent of the population (OLFACAT study, 2003), with 0.3 percent experiencing complete loss of smell.

Causes range from aging, injury, smoking, and neurodegenerative diseases to certain medications.

The researchers discovered that the lab-grown HBCs were able to fill in olfactory lesions, generating multiple cell types including Sus cells, basal cells and olfactory sensory neurons.

The HBCs in culture remained quiescent, pretty much as they do in vivo, but they were able to trigger them into an active state to start the process of differentiation into various olfactory epithelial cells just before engrafting them into injured tissue.

The trigger used was retinoic acid, which has the effect of lowering levels of the protein P63 in the cells, leading to stem cell activation.

P63 functions as a "master control switch" and is known to decrease levels during injury, transitioning HBCs from dormancy to activation in vivo.

A more thorough understanding of the role of P63 has been hampered by the slow pace of in vivo studies. With lab-grown HBCs, the mechanisms of activation can be examined more closely.

"Now that we can create a reserve of dormant stem cells, we see this as a useful tool for exploring ways to guide cell differentiation toward specific cell types, and develop new stem cell therapies for tissue and sensory regeneration--using the patient's own stem cells for culturing and transplantation, or pharmacological interventions to activate the patient's own dormant stem cells within the nose," said Schwob.

Citation: Jesse Peterson et al., Activating a Reserve Neural Stem Cell Population In Vitro Enables Engraftment and Multipotency after Transplantation.

Stem Cell Reports, March 28, 2019; DOI: 10.1016/j.stemcr.2019.02.014


Contact: James E. Schwob,
COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Advanced Stem Cell Technology
Publication:Stem Cell Research News
Date:Apr 8, 2019
Previous Article:FDA Approves Zhong Ensheng's Clinical Phase 2 Trial of Allogeneic Stem Cells In U.S.
Next Article:Newly-Developed Hydrogel Enhances Cell Encapsulation, Delivery.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters